Hemangiopericytoma

WikiDoc Resources for Hemangiopericytoma
Articles
Most recent articles on Hemangiopericytoma Most cited articles on Hemangiopericytoma Review articles on Hemangiopericytoma Articles on Hemangiopericytoma in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Hemangiopericytoma Images of Hemangiopericytoma Photos of Hemangiopericytoma Podcasts & MP3s on Hemangiopericytoma Videos on Hemangiopericytoma
Evidence Based Medicine
Cochrane Collaboration on Hemangiopericytoma Bandolier on Hemangiopericytoma TRIP on Hemangiopericytoma
Clinical Trials
Ongoing Trials on Hemangiopericytoma at Clinical Trials.gov Trial results on Hemangiopericytoma Clinical Trials on Hemangiopericytoma at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Hemangiopericytoma NICE Guidance on Hemangiopericytoma NHS PRODIGY Guidance FDA on Hemangiopericytoma CDC on Hemangiopericytoma
Books
Books on Hemangiopericytoma
News
Hemangiopericytoma in the news Be alerted to news on Hemangiopericytoma News trends on Hemangiopericytoma
Commentary
Blogs on Hemangiopericytoma
Definitions
Definitions of Hemangiopericytoma
Patient Resources / Community
Patient resources on Hemangiopericytoma Discussion groups on Hemangiopericytoma Patient Handouts on Hemangiopericytoma Directions to Hospitals Treating Hemangiopericytoma Risk calculators and risk factors for Hemangiopericytoma
Healthcare Provider Resources
Symptoms of Hemangiopericytoma Causes & Risk Factors for Hemangiopericytoma Diagnostic studies for Hemangiopericytoma Treatment of Hemangiopericytoma
Continuing Medical Education (CME)
CME Programs on Hemangiopericytoma
International
Hemangiopericytoma en Espanol Hemangiopericytoma en Francais
Business
Hemangiopericytoma in the Marketplace Patents on Hemangiopericytoma
Experimental / Informatics
List of terms related to Hemangiopericytoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Maria Fernanda Villarreal, M.D. [2]

Synonyms and keywords: HPC;

Overview

Hemangiopericytoma (HPC) is a type of soft tissue vascular sarcoma that originates in the pericytes in the walls of capillaries. Typically, hemangiopericytomas have large vessels especially located at its periphery, and commonly involve the lower limbs (35% of cases), especially the thigh, pelvis andretroperitoneum (25%).

Historical Perspective

• Hemangiopericytoma was first described by Arthur Purdy Stout and Margaret Ransone Murray, two American pathologists, in 1942.

Classification

• Hemangiopericytoma may be classified into 4 groups:

• Hemangiopericytoma of the spleen
• Dural haemangiopericytomas
• Myopericytoma
• Infantile myofibromatosis
• Sinonasal HPCs.

Pathophysiology

• Hemangiopericytomas arise from pericytes, which are normally involved in the formation of capillaries walls.
• The NF2 gene mutation has been associated with the development of hemangiopericytoma.
• On gross pathology, characteristic findings of hemangiopericytoma, include:

• Poorly demarcated

• On microscopic histopathological analysis, characteristic findings of hemangiopericytoma, include:

Causes

• Hemangiopericytoma may be caused by either [cause1], [cause2], or [cause3].
• Hemangiopericytoma is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
• There are no established causes for hemangiopericytoma.

Differentiating Hemangiopericytoma From Other Diseases

• Hemangiopericytoma must be differentiated from other diseases that cause a slow growing painless mass, such as:

• Liposarcoma
• Sinovial sarcoma
• Angiosarcoma

Epidemiology and Demographics

• The prevalence of hemangiopericytoma is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of hemangiopericytoma was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop hemangiopericytoma.

• Hemangiopericytoma is more commonly observed among patients aged [age range] years old.
• Hemangiopericytoma is more commonly observed among [elderly patients/young patients/children].

Gender

• Hemangiopericytoma affects men and women equally.

• [Gender 1] are more commonly affected with hemangiopericytoma than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for hemangiopericytoma.

• Hemangiopericytoma usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop hemangiopericytoma.

Risk Factors

• Common risk factors in the development of hemangiopericytoma are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with hemangiopericytoma are asymptomatic.
• Early clinical features include painless mass, or slow enlargement.
• If left untreated, the majority of patients with hemangiopericytoma may progress to develop bone invasion.
• Common complications of hemangiopericytoma, may include:

• May profusely bleed during resection.

• The mean survival rate of patients with hemangiopericytoma is approximately 13 years.

• 1-year survival rate is 95%
• 5-year survival rate is 82%
• 10-year survival rate is 60%
• 20-year survival rate is 23%

Diagnosis

Symptoms

• Hemangiopericytoma is usually asymptomatic.
• Symptoms of hemangiopericytoma may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with hemangiopericytoma usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with hemangiopericytoma.

• A [positive/negative] [test name] is diagnostic of hemangiopericytoma.
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of hemangiopericytoma.
• Other laboratory findings consistent with the diagnosis of hemangiopericytoma include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with hemangiopericytoma.

• [Imaging study 1] is the imaging modality of choice for hemangiopericytoma.
• On [imaging study 1], hemangiopericytoma is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• Hemangiopericytoma may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for hemangiopericytoma; the mainstay of therapy is supportive care.

• The mainstay of therapy for hemangiopericytoma is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for hemangiopericytoma.
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of hemangiopericytoma.
• [Surgical procedure] can only be performed for patients with [disease stage] hemangiopericytoma.

Prevention

• There are no primary preventive measures available for hemangiopericytoma.

• Effective measures for the primary prevention of hemangiopericytoma include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with hemangiopericytoma are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].